Hefei Lifeon Pharmaceutical (003020.SZ): Two products are expected to be selected for the national centralized procurement of medicines.
Cubefarm Pharmaceutical (003020.SZ) announced that the company recently participated in the application for the national organized centralized procurement of pharmaceuticals (Batch 12). According to the "Announcement of Proposed Selection Results for Batch 12 of the National Organized Centralized Procurement of Pharmaceuticals" released by the National Organization of Pharmaceutical Joint Procurement Office on July 31, 2026, some of the company's products are proposed to be selected for this centralized procurement, specifically: Doxazosin Mesylate Sustained-Release Tablets and Irbesartan Potassium Tablets.
Hefei Lifeon Pharmaceutical (003020.SZ) announced that the company has recently participated in the application for the national organization of centralized volume-based procurement of pharmaceuticals (the 12th batch). According to the "Notice of Proposed Selection Results for the 12th Batch of National Organization of Centralized Volume-Based Procurement" released by the National Organization of Drug Joint Procurement Office on July 31, 2026, some of the company's products are proposed to be selected for this volume-based procurement. The relevant products are: Doxazosin Mesylate Sustained-Release Tablets, and Losartan Potassium Tablets.
Related Articles
DEFENG SOLIFE (08403) has entered into a cooperation agreement with Beijing Central Good Goods.
Jitai Technology (07666) AI formulation innovation platform launched at Jiangsu Hengrui Pharmaceuticals to accelerate NanoForge commercialization.
LEE & MAN PAPER (02314) will distribute an interim dividend of HKD 0.112 per share on September 3.
DEFENG SOLIFE (08403) has entered into a cooperation agreement with Beijing Central Good Goods.
Jitai Technology (07666) AI formulation innovation platform launched at Jiangsu Hengrui Pharmaceuticals to accelerate NanoForge commercialization.
LEE & MAN PAPER (02314) will distribute an interim dividend of HKD 0.112 per share on September 3.
RECOMMEND
